FUJIFILM Diosynth Biotechnologies Expands Cell Culture Manufacturing Capacity
FUJIFILM Diosynth Biotechnologies has announced the continued expansion of its cell culture manufacturing capabilities with...
One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells.
The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as 'leaky' expression (expression of recombinant protein in the absence of inducer).
How it works
The use of a number of powerful E. coli RNA polymerase promoters, such as T7A3, λpL and tac, opens up a large host range in comparison with the popular T7 system that is limited to hosts carrying the λDE3 prophage.
Download to find out more.
FUJIFILM Diosynth Biotechnologies has announced the continued expansion of its cell culture manufacturing capabilities with...
Fujifilm Diosynth Biotechnologies has announced continued expansion of its process development capabilities with the investment...
Fujifilm Diosynth Biotechnologies has formally opened its new UK mammalian cell culture cGMP manufacturing facility...
Fujifilm Diosynth Biotechnologies has announced that it has received a renewal of its manufacturer's licence...